Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
International Journal of Cancer
|
July 18, 2000
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer
R Silvestrini, A Luisi, M Zambetti, et al.
Tumori
|
June 30, 1985
Accuracy of the double contrast enema in evaluation of the abdominal diffusion of ovarian carcinoma
G Cozzi, L Balzarini, M Bellomi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2001
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
M Zambetti, A Moliterni, C Materazzo, et al.
Breast Cancer Research and Treatment
|
June 16, 1999
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'
R Demicheli, R Miceli, C Brambilla, et al.
Tumori
|
December 10, 1999
Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathologic evaluation of residual disease
G Trecate, E Ceglia, F Stabile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 1999
Combined sequential approach in locally advanced breast cancer
M Zambetti, S Oriana, P Quattrone, et al.
La Radiologia Medica
|
August 4, 1998
[Locally advanced breast tumors. Role of magnetic resonance in the assessment of response to preoperative therapy and of neoplastic residue before the operation]
G Trecate, E Ceglia, F Stabile, et al.
Clinical & Experimental Metastasis
|
April 1, 1983
T3b-T4 breast cancer: factors affecting results in combined modality treatments
P Valagussa, M Zambetti, P Bignami, et al.
Journal of the National Cancer Institute. Monographs
|
January 1, 1992
Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients
M Zambetti, G Bonadonna, P Valagussa, et al.
Breast Cancer Research and Treatment
|
January 1, 1996
Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study
M Terenziani, R Demicheli, C Brambilla, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
International Journal of Cancer
|
July 18, 2000
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer
R Silvestrini, A Luisi, M Zambetti, et al.
Tumori
|
June 30, 1985
Accuracy of the double contrast enema in evaluation of the abdominal diffusion of ovarian carcinoma
G Cozzi, L Balzarini, M Bellomi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2001
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
M Zambetti, A Moliterni, C Materazzo, et al.
Breast Cancer Research and Treatment
|
June 16, 1999
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'
R Demicheli, R Miceli, C Brambilla, et al.
Tumori
|
December 10, 1999
Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathologic evaluation of residual disease
G Trecate, E Ceglia, F Stabile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 1999
Combined sequential approach in locally advanced breast cancer
M Zambetti, S Oriana, P Quattrone, et al.
La Radiologia Medica
|
August 4, 1998
[Locally advanced breast tumors. Role of magnetic resonance in the assessment of response to preoperative therapy and of neoplastic residue before the operation]
G Trecate, E Ceglia, F Stabile, et al.
Clinical & Experimental Metastasis
|
April 1, 1983
T3b-T4 breast cancer: factors affecting results in combined modality treatments
P Valagussa, M Zambetti, P Bignami, et al.
Journal of the National Cancer Institute. Monographs
|
January 1, 1992
Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients
M Zambetti, G Bonadonna, P Valagussa, et al.
Breast Cancer Research and Treatment
|
January 1, 1996
Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study
M Terenziani, R Demicheli, C Brambilla, et al.
Page
of 5